Healthcare
GSK to Acquire RAPT Therapeutics for $2.2 Billion, Strengthening Its Immunology Pipeline
Deal delivers global rights to experimental food allergy therapy ozureprubart as GSK pursues growth under new CEO Luke Miels. Britain’s...
XTL Biopharmaceuticals Makes Bold Bet on Autism Breakthrough with NeuroNOS Acquisition
Transformative deal targets the biological roots of autism, opening a new frontier in disease-modifying therapy. XTL Biopharmaceuticals has taken a...
Alumis Breaks Out With Promising Psoriasis Data
Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110%...
Ironwood Pharmaceuticals Lays Out Ambitious 2026 Outlook
Strong LINZESS growth, rising profitability, and pipeline progress underpin confidence despite pricing changes Ironwood Pharmaceuticals (IRWD) entered 2026 with a...
FDA Approves YARTEMLEA as First-Ever Treatment for TA-TMA
Omeros secures landmark approval for a life-saving therapy in adults and children following stem cell transplant The U.S. Food and...
Processa Pharmaceuticals Reports Promising Phase 2 Results for Breast Cancer Therapy
NGC-Cap shows enhanced cancer-killing exposure with comparable safety ahead of 2026 interim analysis Processa Pharmaceuticals (PCSA) provided a positive clinical...
Markets Split as Pfizer Slumps, Circle Soars on Visa Partnership
Earnings guidance, analyst calls, and commodity moves drive sharp stock reactions U.S. stocks delivered a mixed performance Tuesday as investors...
Pfizer Flags Softer 2026 Outlook as COVID-19 Sales Continue to Fade
Lower demand for pandemic-era products weighs on earnings and revenue forecasts Pfizer (PFE) shares edged lower in premarket trading on...
Structure Therapeutics Reports Breakthrough Weight-Loss Results for Oral GLP-1 Candidate Aleniglipron
Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential...
Polyrizon Achieves Key Manufacturing Milestone for Its Intranasal Allergy Protection Platform
Successful scale-up of PL-14 production paves the way for 2026 clinical trials and future commercial readiness. Polyrizon (PLRZ), a biotechnology...
